Integral Diagnostics Ltd (ASX: IDX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Integral Diagnostics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $577.89 million
P/E Ratio 20.28
Dividend Yield 2.43%
Shares Outstanding 233.96 million
Earnings per share 0.106
Dividend per share 0.05
Year To Date Return 30.97%
Earnings Yield 4.93%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Integral Diagnostics Ltd (ASX: IDX)
    Latest News

    a woman
    ⏸️ Investing

    Top broker tipping this small cap to bounce back into favour after period of purgatory

    This small cap has been struggling recently and is underperforming its peers like Sonic Healthcare Limited (ASX:SHL) and Healthscope Ltd…

    Read more »

    a woman
    ⏸️ Investing

    Integral Diagnostics Ltd reports: Underlying NPAT up 22.7%

    Integral Diagnostics Ltd (ASX:IDX) reported a good set of numbers today.

    Read more »

    a woman
    ⏸️ Investing

    Why I think Integral Diagnostics Ltd could be a buy

    There’s been a bit of interest lately in Integral Diagnostics Ltd (ASX:IDX) lately. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    Why WAM Microcap Limited owns shares of this company

    WAM Microcap Limited (ASX:WMI) owns shares of Integral Diagnostics Ltd (ASX:IDX).

    Read more »

    a woman
    ⏸️ Investing

    These 3 shares had a brilliant 2018

    Here are 3 shares that have made investors happy in 2017…

    Read more »

    a woman
    ⏸️ Investing

    Capitol Health Ltd lobs takeover bid for Integral Diagnostics Ltd

    Capitol Health Ltd (ASX:CAJ) is back on the acquisition trail.

    Read more »

    a woman
    ⏸️ Investing

    Why the Big Un Ltd share price shot up 20%

    The Big Un Ltd (ASX:BIG) share price has been bouncing around a bit lately. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    5 shares you need to watch on Wednesday

    Capitol Health (ASX:CAJ) has launched a takeover offer for Integral Diagnostics (ASX:IDX)

    Read more »

    a woman
    ⏸️ Investing

    The 10 least short-sold shares on the ASX

    Companies like Aspen Group Limited (ASX:APZ), Lovisa Holdings Ltd (ASX:LOV), and Afterpay Touch Limited (ASX:APT) have trifling amounts of interest…

    Read more »

    a woman
    ⏸️ Investing

    Top broker names 11 small caps to buy now

    Small caps are well placed to outperform their larger rivals in FY18. Here are 11 small gems that Credit Suisse…

    Read more »

    a woman
    ⏸️ Investing

    Why these 3 ASX shares just hit 52-week lows

    The Domino's Pizza Enterprises Ltd. (ASX:DMP) share price is one of three to have just hit a new 52-week low.…

    Read more »

    a woman
    ⏸️ Investing

    These 6 stocks have dropped more than 18% in the past week

    The S&P/ASX 300 gained 1.3% over the past week, but these 6 stocks have each lost more than 18%

    Read more »

    Frequently Asked Questions

    Yes, Integral Diagnostics historically pays two fully franked dividends a year.

    Integral Diagnostics generally pays its shareholder dividends in April and October.

    Integral Diagnostics Ltd listed on the ASX on 21 October 2015.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    29 Feb 2024 $0.0250 100.00% Interim 02 Apr 2024
    31 Aug 2023 $0.0350 100.00% Final 04 Oct 2023
    02 Mar 2023 $0.0250 100.00% Interim 04 Apr 2023
    01 Sep 2022 $0.0300 100.00% Final 05 Oct 2022
    01 Mar 2022 $0.0400 100.00% Interim 04 Apr 2022
    02 Sep 2021 $0.0700 100.00% Final 06 Oct 2021
    01 Mar 2021 $0.0550 100.00% Interim 06 Apr 2021
    28 Aug 2020 $0.0400 100.00% Final 01 Oct 2020
    28 Feb 2020 $0.0550 100.00% Interim 07 Apr 2020
    30 Aug 2019 $0.0500 100.00% Final 02 Oct 2019
    01 Mar 2019 $0.0500 100.00% Interim 02 Apr 2019
    31 Aug 2018 $0.0400 100.00% Final 04 Oct 2018
    31 Jan 2018 $0.0400 100.00% Interim 05 Mar 2018
    31 Aug 2017 $0.0000 100.00% Final 04 Oct 2017
    28 Feb 2017 $0.0300 100.00% Interim 30 Mar 2017
    31 Aug 2016 $0.0400 100.00% Final 04 Oct 2016

    IDX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Integral Diagnostics Ltd

    Integral Diagnostics Ltd (ASX: IDX) is an Australian healthcare services company providing medical imaging services. 

    The group operates in a single business providing diagnostic imaging to general practitioners, medical specialists, and allied health professionals and their patients. 

    The company operates more than 90 radiology clinics across Australia and New Zealand. It is also a joint venture partner in Medx, expanding its services to the United Kingdom and Ireland.

    IDX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    19 Apr 2024 $2.47 $-0.01 -0.40% 317,049 $2.49 $2.49 $2.45
    18 Apr 2024 $2.48 $0.03 1.22% 477,965 $2.47 $2.49 $2.44
    17 Apr 2024 $2.45 $0.03 1.24% 544,580 $2.45 $2.47 $2.41
    16 Apr 2024 $2.42 $0.05 2.11% 557,284 $2.41 $2.43 $2.35
    15 Apr 2024 $2.37 $0.00 0.00% 319,773 $2.38 $2.38 $2.35
    12 Apr 2024 $2.37 $0.01 0.42% 279,727 $2.36 $2.38 $2.33
    11 Apr 2024 $2.36 $-0.02 -0.84% 175,083 $2.35 $2.39 $2.34
    10 Apr 2024 $2.38 $-0.01 -0.42% 587,508 $2.40 $2.40 $2.35
    09 Apr 2024 $2.39 $-0.01 -0.42% 296,650 $2.40 $2.43 $2.38
    08 Apr 2024 $2.40 $0.02 0.84% 394,144 $2.41 $2.42 $2.37
    05 Apr 2024 $2.38 $0.02 0.85% 458,483 $2.35 $2.39 $2.32
    04 Apr 2024 $2.36 $-0.07 -2.88% 500,053 $2.43 $2.43 $2.33
    03 Apr 2024 $2.43 $0.16 7.05% 1,275,061 $2.26 $2.43 $2.25
    02 Apr 2024 $2.27 $0.02 0.89% 779,869 $2.28 $2.30 $2.23
    28 Mar 2024 $2.25 $0.03 1.35% 222,587 $2.23 $2.26 $2.22
    27 Mar 2024 $2.22 $-0.04 -1.77% 384,949 $2.25 $2.26 $2.21
    26 Mar 2024 $2.26 $0.01 0.44% 771,319 $2.23 $2.27 $2.19
    25 Mar 2024 $2.25 $0.03 1.35% 722,006 $2.21 $2.27 $2.21
    22 Mar 2024 $2.22 $-0.02 -0.89% 227,676 $2.22 $2.24 $2.19

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    02 Apr 2024 James Hall Issued 1,719 $3,748
    Dividend Reinvestment Plan (DRP). As per announcement on 04-04-2024
    02 Apr 2024 James Hall Issued 1,719 $3,748
    Dividend Reinvestment Plan (DRP).
    01 Dec 2023 Andrew Fay Buy 15,000 $25,575
    On-market trade.
    01 Dec 2023 Ian Kadish Buy 20,000 $35,050
    On-market trade.
    30 Nov 2023 Ian Kadish Issued 248,970 $441,921
    Issue of securities. 858,583 - Rights
    30 Nov 2023 Ingrid Player Buy 35,000 $60,725
    On-market trade.
    30 Nov 2023 James Hall Buy 150,000 $258,225
    On-market trade.
    20 Sep 2023 Ian Kadish Issued 26,035 $75,241
    Issue of securities. 6,09,613 Performance Rights
    28 Aug 2023 Ian Kadish Expiry 435,572 $1,354,628
    As advised by the company. Lapse of rights, 583,578 Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Andrew James Fay Non-Executive Director Jul 2022
    Mr Fay brings to the Board over 30 years of experience in funds and investment management, including Chief Executive Officer and Chief Investment Officer roles at Deutsche Asset Management (Australia) Limited. He also held several other senior investment roles at Deutsche Asset Management and previously at AMP Capital. From 1998 to 2006, he was a member of the Investment Board Committee of the Financial Services Council. Andrew is an experienced company director across ASX listed, private and regulated entities and accordingly brings to the Board skills in financial and risk management, capital markets, executive remuneration frameworks, strategy, investment, and corporate governance. Specifically, he has sector experience and expertise in financial services, including investment, funds, property and infrastructure management. He is also Member of the Risk and Compliance Committee.
    Dr Jacqueline Milne Executive Director Nov 2019
    Dr Milne Dr Milne is a full-time permanently employed radiologist of the Company based in Queensland and is therefore considered by the Board to be a Non-Independent Executive Director. While Dr Milne is not an independent director by virtue of her employment, she is independent of senior management and her responsibilities do not extend to the day-to-day management of the Company. She is Member of the Integral Clinical Leadership Committee.
    Ms Raelene Margaret Murphy Non-Executive Director Oct 2017
    Ms Murphy has over 30 years of experience in strategic, financial, and operational leadership in both industry and professional advisory, after beginning her career in audit. She was formerly a Partner in a national accounting firm, Managing Director of Korda Mentha and CEO of the Delta Group. In her professional advisory career, she specialized in operational and financial restructuring, with a particular emphasis on merger and acquisition integration across a range of public and private companies. Raelene is a Fellow of Chartered Accountants Australia and New Zealand and has extensive experience as Chair of Audit and Risk Committees for ASX listed companies. She is Chair of the Risk and Compliance Committee.
    Ms Ingrid Anne Player Non-Executive Director Aug 2023
    Ms Player has more than 20 years experience in the healthcare industry, gained from leadership roles across the private, public and not for profit sectors. In her executive career, Ms Player was Group Executive Legal, Governance and Sustainability at Healthscope, one of Australias largest private healthcare providers. As a qualified lawyer, she previously worked in private legal practice in Australia and Europe specialising in corporate law, M&A and capital markets. She brings to the Board experience in leveraging corporate transactions and major capital projects to achieve strategic outcomes, as well as skills in risk management, government relations, sustainability and corporate governance. She currently serves as a Non-Executive Director of Cleanaway Management Ltd (ASX:CWY), Cogstate Ltd (ASX:CGS), Epworth Foundation and HealthShare Victoria
    Mr James Tobias Hall Non-Executive Director Sep 2023
    Mr Hall has experience in Australia and New Zealand and is an experienced Board and Committee Chair. Mr Hall was Group CEO of St Vincents Health Australia from 2014 to 2022, He has also overseen multisite, for-profit generating businesses at both board and executive levels in employment services, early learning services and aged care. His experience in M&A includes the acquisition of ABC Childcare from administration. Mr Hall is currently non-executive Chair of Sana Health Group, non-executive Chair of For Purpose Aged Care, non-executive Director of UNICEF Australia, a trustee of Yajilarra (a philanthropic foundation) and advisory board member for Fujitsu Australia and New Zealand. His former non-executive roles include Chair of ASX listed Sterihealth, board member of Goodstart Early Learning, board member of Working Links (a UK based for profit employment service) and two New Zealand based community built regional hospitals.
    Dr Ian Kadish Chief Executive OfficerManaging Director May 2017
    Mr Kadish began his career as a medical doctor in Johannesburg, South Africa. Ian was helpful in growing the group from five hospitals with a market capitalisation of $60m, to 119 hospitals and a market capitalisation of $3bn. Since migrating to Australia in 2006, Dr Kadish's roles have included CEO and MD of Healthcare Australia, CEO and MD of Pulse Health Group and CEO of Laverty Pathology. He is also a Director of the Australian Diagnostic Imaging Association (ADIA). He is also Member of the Integral Clinical Leadership Committee.
    Ms Nikki Dalla Valle Company Secretary Dec 2023
    -
    Craig White Chief Financial Officer
    -
    Paul McCrow Chief Operating Officer
    -
    Nikki Dalla Valle Company Secretary
    -
    Jacqueline Milne Radiologist Executive Director
    -
    Nazar Bokani Radiologist Executive Director
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 41,305,475 17.73%
    Citicorp Nominees Pty Limited 37,720,613 16.19%
    J P Morgan Nominees Australia Pty Limited 30,949,506 13.28%
    National Nominees Limited 12,416,583 5.33%
    BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <DRP A/C> 4,309,344 1.85%
    BNP Paribas Noms Pty Ltd <DRP> 3,943,475 1.69%
    Hsbc Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 3,469,048 1.49%
    New Imaging Pty Ltd <New Imaging A/C> 3,389,045 1.45%
    Washington H Soul Pattinson And Company Limited 3,290,936 1.41%
    Citicorp Nominees Pty Limited <Colonial First State INV A/C> 3,276,722 1.41%
    Lethean Holdings Pty Ltd <Howitt No 8 A/C> 2,944,760 1.26%
    J A Mullins Pty Ltd <James A Mullins Family A/C> 2,616,051 1.12%
    Firbar Pty Ltd <The Howitt No 4 A/C> 2,357,230 1.01%
    Lockwood Ridge Pty Ltd <The AJ French Family A/C> 2,177,058 0.93%
    Mittal Holdings Pty Ltd <Howitt No 12 A/C> 2,085,907 0.90%
    Mr Vincent Michael O'sullivan <O'sullivan A/C> 2,059,000 0.88%
    Wyndham Salter Pty Ltd <The Howitt No 10 A/C> 1,862,947 0.80%
    Masfen Securities Limited 1,710,000 0.73%
    Netwealth Investments Limited <Wrap Services A/C> 1,605,935 0.69%
    BNP Paribas Noms (NZ) Ltd <DRP> 1,509,566 0.65%

    Profile

    since

    Note